Philips compact ultrasound system obtains FDA approval  

NETHERLANDS – The US Food and Drug Administration (FDA) has cleared Ultrasound 5000 Compact, a new portable ultrasound scanner from Philips.

According to the company, the scanner is intended to provide the image quality of cart-based ultrasound in a more portable package.

In addition to general imaging and utility in the obstetrics and gynecology fields, Philips said the Ultrasound 5000 Compact Series enables timely assessments in cardiology and point-of-care ultrasonography.

Using PhilipsUltrasound Collaboration Live teleultrasound capabilities, the Ultrasound 5000 Compact also includes tools for real-time collaboration, remote consultations, and training.

According to the company, it also includes integrated connectivity for streamlined workflows.

Philips noted the portable device provides a combination of enhanced image quality and remote consultation capability (via Philips Ultrasound Collaboration Live tele-ultrasound) that facilitates clinical decision support with mobile efficiency.

Designed to provide clear images that rapidly inform and enable diagnosis confirmation, the solution is said to prevent the need for costly, time-consuming repeat scans.

The device comes with a wide range of clinical capabilities, including real-time collaboration, and wireless connectivity and reporting, said the company.

Philips created the new Ultrasound 5000 Compact Series by combining portability and performance while drawing on its expertise in ultrasound imaging.

It allows clinicians to benefit from its compact design while still delivering clinical decision support with mobile efficiency.

The system enables clinicians to make the correct diagnosis the first time thanks to real-time collaboration, remote consultations and training, and integrated connectivity features.

According to Philips, the compact ultrasound solution has the same user interfaces, features, touchscreens, transducers, and workflows as its EPIQ and Affiniti ultrasound systems.

Boston Imaging, the US headquarters of Samsung’s digital radiography and ultrasound business, recently introduced the V7, a cutting-edge ultrasound system with a variety of clinical applications that improve both the patient and user experience.

The V7 recently received 510(k) clearance for commercial use from the US Food and Drug Administration.

Experts and research trends continue to demonstrate how artificial intelligence (AI) will revolutionize the medical imaging sector in the future.

Medical imaging technologies provide clinicians with accurate and convenient disease screenings, enabling them to detect abnormalities proactively, treat illnesses early on, and enhance patient outcomes.

According to a recent study published in the National Library of Medicine, AI applications have the potential to reduce annual healthcare costs in the United States by US$150 billion by 2026.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.